Sunplus Innovation Technology Inc. (TPEX:5236)
Taiwan · Delayed Price · Currency is TWD 133.50
0.00 (0.00%)
Aug 12, 2025, 1:30 PM CST
Ligand Pharmaceuticals Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2016 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2016 - 2020 |
| 1,959 | 1,818 | 1,650 | 1,542 | 2,288 | 1,824 | Upgrade | |
Revenue Growth (YoY) | 15.94% | 10.17% | 7.03% | -32.63% | 25.47% | 92.71% | Upgrade |
Cost of Revenue | 813.9 | 731.3 | 633.61 | 597.31 | 848.86 | 782.21 | Upgrade |
Gross Profit | 1,145 | 1,087 | 1,016 | 944.41 | 1,440 | 1,042 | Upgrade |
Selling, General & Admin | 197.68 | 195.71 | 183.23 | 221.62 | 355.82 | 270.72 | Upgrade |
Research & Development | 411.09 | 371.09 | 358.95 | 285.67 | 309.66 | 196.88 | Upgrade |
Other Operating Expenses | - | - | 0.01 | - | - | - | Upgrade |
Operating Expenses | 608.77 | 566.8 | 542.19 | 507.29 | 665.48 | 467.6 | Upgrade |
Operating Income | 536.7 | 519.83 | 474.25 | 437.12 | 774.16 | 574.13 | Upgrade |
Interest Expense | -1.18 | -1.2 | -0.66 | -0.18 | -0.26 | -0.46 | Upgrade |
Interest & Investment Income | 30.54 | 29.68 | 26.35 | 16.14 | 7.25 | 5.89 | Upgrade |
Currency Exchange Gain (Loss) | 9.19 | 12.7 | -4.51 | -2.6 | 0.38 | -4.99 | Upgrade |
Other Non Operating Income (Expenses) | -7.01 | -3.28 | 3.89 | 12.3 | 2.97 | 2.98 | Upgrade |
EBT Excluding Unusual Items | 568.25 | 557.72 | 499.33 | 462.77 | 784.51 | 577.55 | Upgrade |
Gain (Loss) on Sale of Investments | 6.97 | 7.19 | 5.8 | 2.95 | 0.97 | 0.68 | Upgrade |
Pretax Income | 575.22 | 564.92 | 505.13 | 465.73 | 785.47 | 578.22 | Upgrade |
Income Tax Expense | 84.99 | 82.85 | 77.34 | 92.41 | 150.03 | 110.56 | Upgrade |
Net Income | 490.23 | 482.07 | 427.79 | 373.32 | 635.44 | 467.67 | Upgrade |
Net Income to Common | 490.23 | 482.07 | 427.79 | 373.32 | 635.44 | 467.67 | Upgrade |
Net Income Growth | 2.34% | 12.69% | 14.59% | -41.25% | 35.87% | 244.76% | Upgrade |
Shares Outstanding (Basic) | 60 | 60 | 60 | 59 | 55 | 53 | Upgrade |
Shares Outstanding (Diluted) | 60 | 60 | 60 | 60 | 56 | 53 | Upgrade |
Shares Change (YoY) | 0.05% | 0.11% | 0.71% | 6.19% | 5.74% | 0.23% | Upgrade |
EPS (Basic) | 8.17 | 8.03 | 7.17 | 6.35 | 11.52 | 8.85 | Upgrade |
EPS (Diluted) | 8.15 | 8.03 | 7.13 | 6.27 | 11.33 | 8.81 | Upgrade |
EPS Growth | 2.09% | 12.57% | 13.66% | -44.63% | 28.51% | 244.11% | Upgrade |
Free Cash Flow | 452.22 | 462.75 | 549.13 | 203.59 | 835.21 | 487.37 | Upgrade |
Free Cash Flow Per Share | 7.53 | 7.71 | 9.15 | 3.42 | 14.89 | 9.19 | Upgrade |
Dividend Per Share | 6.972 | 6.972 | 6.818 | 6.818 | - | 7.792 | Upgrade |
Dividend Growth | 2.26% | 2.26% | -0.00% | - | - | 240.43% | Upgrade |
Gross Margin | 58.46% | 59.77% | 61.60% | 61.26% | 62.91% | 57.11% | Upgrade |
Operating Margin | 27.39% | 28.59% | 28.74% | 28.35% | 33.83% | 31.48% | Upgrade |
Profit Margin | 25.02% | 26.52% | 25.93% | 24.21% | 27.77% | 25.64% | Upgrade |
Free Cash Flow Margin | 23.08% | 25.45% | 33.28% | 13.21% | 36.50% | 26.72% | Upgrade |
EBITDA | 545.95 | 528.55 | 479.78 | 442.69 | 778.47 | 576.81 | Upgrade |
EBITDA Margin | 27.86% | 29.07% | 29.08% | 28.71% | 34.02% | 31.62% | Upgrade |
D&A For EBITDA | 9.25 | 8.72 | 5.53 | 5.57 | 4.31 | 2.68 | Upgrade |
EBIT | 536.7 | 519.83 | 474.25 | 437.12 | 774.16 | 574.13 | Upgrade |
EBIT Margin | 27.39% | 28.59% | 28.74% | 28.35% | 33.83% | 31.48% | Upgrade |
Effective Tax Rate | 14.77% | 14.67% | 15.31% | 19.84% | 19.10% | 19.12% | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.